Shield Therapeutics up 27% after impromptu trading update
Portfolio Pulse from
Shield Therapeutics' shares rose 27% following a trading update revealing strong sales of its iron deficiency drug ACCRUFeR, with an increased net selling price. The company is on track to meet its 2024 revenue target, crucial for its debt agreement with SWK Funding.
November 21, 2024 | 9:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shield Therapeutics' shares surged 27% due to strong sales of ACCRUFeR and an increased net selling price, aligning with its 2024 revenue target.
The significant increase in share price is directly linked to the strong sales performance and price increase of ACCRUFeR, which supports the company's revenue target crucial for its debt agreement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100